Armenian Translation

Astellas enters into contract with Medivation to develop MDV3100 Astellas Pharma Inc.

Astellas enters into contract with Medivation to develop MDV3100 Astellas Pharma Inc. and Medivation, Inc. announced today that they have entered right into a global contract to develop and commercialize MDV3100, Medivation’s investigational drug for the treatment of prostate cancer http://www.amoxil.net/ http://amoxil.net . MDV3100 happens to be getting evaluated in the Stage 3 AFFIRM clinical trial in guys with castration-resistant prostate tumor who had been previously treated with docetaxel-based chemotherapy. Under the conditions of the agreement, Medivation will receive an up-front cash payment of $110 million.